ROSEN Law Firm Encourages REGENXBIO Investors to Secure Counsel Before Deadline

Securities class action lawsuit filed against REGENXBIO, Inc. over alleged misleading statements about drug candidate RGX-111

Mar. 26, 2026 at 11:18pm

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, has filed a securities class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of investors who purchased the company's securities between February 9, 2022 and January 27, 2026. The lawsuit alleges that REGENXBIO made misleading statements about the efficacy and safety of its RGX-111 drug candidate, a one-time gene therapy for the treatment of Mucopolysaccharidosis Type I. The firm is encouraging investors who purchased REGENXBIO securities during this period to secure counsel before the April 14, 2026 lead plaintiff deadline.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures from pharmaceutical companies, especially those developing novel gene therapies. Investors rely on truthful information to make informed decisions, and any alleged misleading statements could result in significant financial losses. The outcome of this case could set precedents around disclosure requirements in the rapidly evolving gene therapy industry.

The details

The class action lawsuit alleges that REGENXBIO provided investors with overly positive assertions about the future success of its RGX-111 drug candidate based on continuing positive biomarker and safety data from an ongoing Phase I/II study. However, the lawsuit claims that the company was simultaneously disseminating false and misleading statements or concealing material adverse facts about the actual efficacy and safety of the RGX-111 trial. When the true details about the drug's performance allegedly entered the market, investors suffered damages.

  • The class period covers purchases of REGENXBIO securities between February 9, 2022 and January 27, 2026.
  • The lead plaintiff deadline is April 14, 2026.

The players

REGENXBIO, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare genetic diseases.

Rosen Law Firm

A global investor rights law firm that has filed the securities class action lawsuit against REGENXBIO on behalf of investors.

Got photos? Submit your photos here. ›

What’s next

Investors who purchased REGENXBIO securities during the class period have until April 14, 2026 to file as lead plaintiff in the securities class action lawsuit.

The takeaway

This case underscores the need for pharmaceutical companies to provide accurate and transparent information to investors, especially regarding the development of novel therapies. The outcome could set important precedents around disclosure requirements in the gene therapy industry.